Cytogenetic testing for therapeutic indication in cancer

References

• Bueso-Ramos CE, Cortes J, Talpaz M et al. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer101(2), 332–336 (2004).
   PubMed Web of Science ®Google Scholar
• Kauraniemi P, Hautaniemi S, Autio R et al. Effects of herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene23(4), 1010–1013 (2004).
   PubMed Web of Science ®Google Scholar
• Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res.64(7), 2343–2346 (2004).
   PubMed Web of Science ®Google Scholar
• Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Ann. Rev. Immunol.22, 247–306 (2004).
   PubMed Web of Science ®Google Scholar
• Volpi A, Nanni O, De Paola F et al. HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. J. Clin. Oncol.21(14), 2708–2712 (2003).
   PubMedGoogle Scholar
• Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science305(5682), 399–401 (2004).
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Kurosu T, Kakihana K, Mizuchi D, Miura O. The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. Biochem. Biophys. Res. Commun.319(4), 1272–1275 (2004).
   PubMedGoogle Scholar
• De Klein A, Van Kessel AG, Grosveld G et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature300(5894), 765–767 (1982).
   PubMed Web of Science ®Google Scholar
• Groffen J, Heisterkamp N. The chimeric BCR-ABL gene. Baillieres Clin. Haematol.10(2), 187–201 (1997).
   PubMedGoogle Scholar
• Sawyers CL, Timson L, Kawasaki ES, Clark SS, Witte ON, Champlin R. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proc. Natl Acad. Sci. USA87(2), 563–567 (1990).
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood94(6), 1848–1854 (1999).
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Bullinger L, Lichter P, Dohner H. German CLL Study Group (GCLLSG). Chronic lymphocytic leukemia. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia16(6), 993–1007 (2002).
   PubMed Web of Science ®Google Scholar
• Eclache V, Caulet-Maugendre S, Poirel HA et al. Cryptic deletion involving the ATM locus at 11q22.3 approximately q23.1 in B-cell chronic lymphocytic leukemia and related disorders. Cancer Genet. Cytogenet.152(1), 72–76 (2004).
   PubMed Web of Science ®Google Scholar
• Burnett AK, Wheatley K, Goldstone AH et al. Medical Research Council Adult and Paediatric Working Parties. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br. J. Haematol.118(2), 385–400 (2002).
   PubMed Web of Science ®Google Scholar
• Sarriera JE, Albitar M, Estrov Z et al. Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing. Leukemia15(1), 57–61 (2001).
   PubMed Web of Science ®Google Scholar
• Borkhardt A, Wuchter C, Viehmann S et al. Infant acute lymphoblastic leukemia – combined cytogenetic, immunophenotypical and molecular analysis of 77 cases. Leukemia16(9), 1685–1690 (2002).
   PubMed Web of Science ®Google Scholar
• Ariffin H, Chen SP, Wong HL, Yeoh A. Validation of a multiplex RT-PCR assay for screening significant oncogene fusion transcripts in children with acute lymphoblastic leukaemia. Singapore Med. J.44(10), 517–520 (2003).
   PubMedGoogle Scholar
• Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature243, 290–293 (1973).
   PubMed Web of Science ®Google Scholar
• Bartram CR, de Klein A, Hagemeijer A et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature306277–280 (1983).
   PubMed Web of Science ®Google Scholar
• Sawyers CL. Chronic myeloid leukemia. N. Engl. J. Med.340(17), 1330–1340 (1999).
   PubMed Web of Science ®Google Scholar
• Gleibner B, Gőkbuget N, Bartram CR et al. German Multicenter Trials of Adult Acute Lymphoblastic Leukemia Study Group. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood99(5), 1536–1543 (2002).
   PubMedGoogle Scholar
• Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood96(10), 3343–3356 (2000).
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Bueso-Ramos CE, Kantarjian H et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J. Clin. Oncol.19(11), 2915–2926 (2001).
   PubMedGoogle Scholar
• Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J. Natl Cancer Inst.25, 85–109 (1960).
   PubMed Web of Science ®Google Scholar
• Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature243(5405), 290–293 (1973).
   PubMed Web of Science ®Google Scholar
• Martiat P, Michaux JL, Rodhain J. Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Francais de Cytogenetique Hematologique. Blood78(1), 205–211 (1991).
   PubMed Web of Science ®Google Scholar
• Salesse S, Verfaillie CM. BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia. Mol. Cancer Ther.2(2), 173–182 (2003).
   PubMed Web of Science ®Google Scholar
• Bakalova R, Ohba H, Zhelev Z, Ishikawa M, Shinohara Y, Baba Y. Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase-a potential reason for resistance to Glivec in chronic myelogenous leukaemia. Biochem. Pharmacol.66(10), 1879–1884 (2003).
   PubMed Web of Science ®Google Scholar
• Storlazzi CT, Specchia G, Anelli L et al. Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients. Genes Chromosomes Cancer35(3), 271–276 (2002).
   PubMed Web of Science ®Google Scholar
• Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br. J. Haematol.118(3), 771–777 (2002).
   PubMed Web of Science ®Google Scholar
• Donato NJ, Wu JY, Stapley J et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood101(2), 690–698 (2003).
   PubMed Web of Science ®Google Scholar
• Gabert J, Beillard E, van der Velden VH et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia17(12), 2318–2357 (2003).
   PubMed Web of Science ®Google Scholar
• Wang YL, Bagg A, Pear W, Nowell PC, Hess JL. Chronic myelogenous leukemia: laboratory diagnosis and monitoring. Genes Chromosomes Cancer32(2), 97–111 (2001).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Cortes JE, O’Brien S et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α Blood104(7), 1979–1988 (2004).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Talpaz M, O’Brien S et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood103(8), 2873–2878 (2004).
   PubMed Web of Science ®Google Scholar
• Cortes JE, Talpaz M, Giles F, O’Brien S et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood101(10), 3794–3800 (2003).
   PubMed Web of Science ®Google Scholar
• Lin F, Kirkland MA, van Rhee FV et al. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant.18(6), 1147–1152 (1996).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Reiter A, Saussele S et al. Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood95(1), 62–66 (2000).
   PubMed Web of Science ®Google Scholar
• Vogt MH, de Paus RA, Voogt PJ, Willemze R, Falkenburg JH. DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood95(3), 1100–1105 (2000).
   PubMedGoogle Scholar
• Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood103(1), 347–352 (2004).
   PubMed Web of Science ®Google Scholar
• Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann. Intern. Med.131(3), 207–219 (1999).
   PubMed Web of Science ®Google Scholar
• Nowell PC. Progress with chronic myelogenous leukemia: a personal perspective over four decades. Ann. Rev. Med.53, 1–13 (2002).
   PubMedGoogle Scholar
• Hess JL. Detection of chromosomal translocations in leukemia. Is there a best way? Am. J. Clin. Pathol.109, 3–5 (1998).
   PubMedGoogle Scholar
• Kantarjian HM, Talpaz M, Cortes J et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin. Cancer Res.9(1), 160–166 (2003).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Weisser A, La Rosee P et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia14(6), 998–1005 (2000).
   PubMedGoogle Scholar
• Hagemeijer A, Buijs A, Smit E, Janssen B, Creemers GJ, Van der Plas D, Grosveld G. Translocation of BCR to chromosome 9: a new cytogenetic variant detected by FISH in two Ph-negative, BCR-positive patients with chronic myeloid leukemia. Genes Chromosomes Cancer8(4), 237–245 (1993).
   PubMed Web of Science ®Google Scholar
• Van der Plas DC, Grosveld G, Hagemeijer A. Review of clinical, cytogenetic, and molecular aspects of Ph-negative CML. Cancer Genet. Cytogenet.52(2), 143–156 (1991).
   PubMed Web of Science ®Google Scholar
• Travis LB, Pierre RV, DeWald GW. Ph1-negative chronic granulocytic leukemia: a nonentity. Am. J. Clin. Pathol.85(2), 186–193 (1986).
   PubMed Web of Science ®Google Scholar
• O’Dwyer ME, Mauro MJ, Druker BJ. Recent advancements in the treatment of chronic myelogenous leukemia. Ann. Rev. Med.53, 369–381 (2002).
   PubMed Web of Science ®Google Scholar
• Sinclair PB, Nacheva EP, Leversha M et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood95(3), 738–743 (2000).
   PubMed Web of Science ®Google Scholar
• Sinclair PB, Green AR, Grace C, Nacheva EP. Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridization system. Blood90(4), 1395–1402 (1997).
   PubMed Web of Science ®Google Scholar
• Dewald GW, Ketterling RP, Wyatt WA, Stupca PJ. Cytogenetic studies in neoplstic hematolgic disorders. In: Clinical Laboratory Medicine, second edition. McClatchey KD (Ed.), Lippincott Williams & Wilkins, PA, USA, 3–30 (2002).
   Google Scholar
• Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med.2(5), 561–566 (1996).
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med.344(14), 1031–1037 (2001).
   PubMed Web of Science ®Google Scholar
• La Rosee P, O’Dwyer ME, Druker BJ. Insights from preclinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia16(7), 1213–1219 (2002).
   PubMed Web of Science ®Google Scholar
• Deininger MW, O’Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J. Clin. Oncol.21(8), 1637–1647 (2003).
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol.4(2), 75–85 (2003).
   PubMed Web of Science ®Google Scholar
• Donato NJ, Wu JY, Stapley J et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res.64(2), 672–677 (2004). Erratum in: Cancer Res.64(6), 2306 (2004).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia18(8), 1321–1331 (2004).
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann. Oncol.10(12), 1419–1432 (1999).
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood103(4), 1202–1210 (2004).
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood94(6), 1848–1854 (1999).
   PubMed Web of Science ®Google Scholar
• Mauro FR, Foa R, Cerretti R et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood95(9), 2786–2792 (2000).
   PubMed Web of Science ®Google Scholar
• Gupta N, Kavuru S, Patel D et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia16(10), 2092–2095 (2002).
   PubMed Web of Science ®Google Scholar
• Mainou-Fowler T, Dignum HM, Proctor SJ, Summerfield GP. The prognostic value of CD38 expression and its quantification in B-cell chronic lymphocytic leukemia (B-CLL). Leuk. Lymphoma45(3), 455–462 (2004).
   PubMed Web of Science ®Google Scholar
• Robak T. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk. Lymphoma45(2), 205–219 (2004).
   PubMed Web of Science ®Google Scholar
• D’Arena G, Di Renzo N, Brugiatelli M, Vigliotti ML, Keating MJ. Biological and clinical heterogeneity of B-cell chronic lymphocytic leukemia. Leuk. Lymphoma44(2), 223–228 (2003).
   PubMed Web of Science ®Google Scholar
• Matthews C, Catherwood M, Morris TC, Alexander HD. Routine analysis of IgVH mutational status in CLL patients using BIOMED-2 standardized primers and protocols. Leuk. Lymphoma45(9), 1899–1904 (2004).
   PubMed Web of Science ®Google Scholar
• Tobin G, Thunberg U, Karlsson K et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood104(9), 2879–2885 (2004)
   PubMed Web of Science ®Google Scholar
• Tobin G, Soderberg O, Thunberg U, Rosenquist R. V(H)3–21 gene usage in chronic lymphocytic leukemia-characterization of a new subgroup with distinct molecular features and poor survival. Leuk. Lymphoma45(2), 221–228 (2004).
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Bullinger L, Lichter P, Dohner H. German CLL Study Group (GCLLSG). Chronic lymphocytic leukemia. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia16(6), 993–1007 (2002).
   PubMed Web of Science ®Google Scholar
• Osorio LM, Jondal M, Aguilar-Santelises M. Regulation of B-CLL apoptosis through membrane receptors and Bcl-2 family proteins. Leuk. Lymphoma30, 247–256 (1998).
   PubMed Web of Science ®Google Scholar
• Schulz H, Klein SK, Rehwald U et al. German CLL Study Group. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood100(9), 3115–3120 (2002).
   PubMed Web of Science ®Google Scholar
• Kalil N, Cheson BD. Management of chronic lymphocytic leukaemia. Drugs Aging16(1), 9–27 (2000).
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Dohner K, Bentz M, Lichter P. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J. Mol. Med.77(2), 266–281 (1999).
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med.343(26), 1910–1916 (2000).
   PubMed Web of Science ®Google Scholar
• Oscier D, Fegan C, Hillmen P et al. Guidelines Working Group of the UK CLL Forum. British Committee for Standards in Haematology. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br. J. Haematol.125(3), 294–317 (2004).
   PubMed Web of Science ®Google Scholar
• Dreger P, Brand R, Hansz J et al. Chronic Leukemia Working Party of the EBMT. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia17(5), 841–848 (2003).
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Keating MJ, Giles FJ et al. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer100(12), 2583–2591 (2004).
   PubMedGoogle Scholar
• Wendtner CM, Ritgen M, Schweighofer CD et al. German CLL Study Group (GCLLSG). Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter Phase III trial of the German CLL Study Group (GCLLSG). Leukemia18(6), 1093–1101 (2004).
   PubMed Web of Science ®Google Scholar
• Jourdan ML, Ferrero-Pous M, Spyratos F, Romain S, Martin PM, Chassevent A. Flow cytometric S-phase fraction measurement in breast carcinoma: Influence of software and histogram resolution. Cytometry48(2), 66–70 (2002).
   PubMedGoogle Scholar
• Cleator S, Ashworth A. Molecular profiling of breast cancer: clinical implications. Br. J. Cancer90(6), 1120–1124 (2004).
   PubMed Web of Science ®Google Scholar
• Korsching E, Packeisen J, Helms MW et al. Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridization (CGH) and immunohistochemistry. Br. J. Cancer90(7), 1422–1428 (2004).
   PubMedGoogle Scholar
• Michels JJ, Marnay J, Delozier T, Denoux Y, Chasle J. Proliferative activity in primary breast carcinomas is a salient prognostic factor. Cancer100(3), 455–464 (2004).
   PubMedGoogle Scholar
• Michels JJ, Duigou F, Marnay J et al. Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma: prognostic significance. Cancer97(6), 1376–1386 (2003).
   PubMedGoogle Scholar
• Michels JJ, Marnay J, Plancoulaine B, Chasle J. Flow cytometry in primary breast carcinomas: prognostic impact of S-phase fraction according to different analysis patterns. Cytometry59B(1), 32–39 (2004).
   Google Scholar
• Michels JJ, Duigou F, Marnay J, Denoux Y, Delozier T, Chasle J. Flow cytometry in primary breast carcinomas: prognostic impact of multiploidy and hypoploidy. Cytometry55B(1), 37–45 (2003).
   Google Scholar
• Fujita T, Kobayashi Y, Wada O et al. Full activation of estrogen receptor alpha activation function-1 induces proliferation of breast cancer cells. J. Biol. Chem.278(29), 26704–26714 (2003).
   PubMedGoogle Scholar
• Ouatas T, Halverson D, Steeg PS. Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells: new uses for old compounds. Clin. Cancer Res.9(10 Pt 1), 3763–3772 (2003).
   PubMed Web of Science ®Google Scholar
• Banerjee M, George J, Song EY, Roy A, Hryniuk W. Tree-based model for breast cancer prognostication. J. Clin. Oncol.22(13), 2567–2575 (2004).
   PubMedGoogle Scholar
• Louie MC, Zou JX, Rabinovich A, Chen HW. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and anti-estrogen resistance. Mol. Cell. Biol.24(12), 5157–5171 (2004).
   PubMed Web of Science ®Google Scholar
• Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res.64(7), 2343–2346 (2004).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Bartlett J, Ellis IO et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J. Pathol.199(4), 418–423 (2003).
   PubMed Web of Science ®Google Scholar
• Ross JS, Fletcher JA, Linette GP et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist8(4), 307–325 (2003).
   PubMed Web of Science ®Google Scholar
• Konecny GE, Thomssen C, Luck HJ et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J. Natl Cancer Inst.96(15), 1141–1151 (2004).
   PubMedGoogle Scholar
• Vicini FA, Baglan KL, Kestin LL et al. Accelerated treatment of breast cancer. J. Clin. Oncol.19(7), 1993–2001 (2001).
   PubMed Web of Science ®Google Scholar
• Vicini FA, Kestin L, Chen P, Benitez P, Goldstein NS, Martinez A. Limited-field radiation therapy in the management of early-stage breast cancer. J. Natl Cancer Inst.95(16), 1205–1210 (2003).
   PubMedGoogle Scholar
• Murakami M, Kuroda Y, Nishimura S et al. Intraarterial infusion chemotherapy and radiotherapy with or without surgery for patients with locally advanced or recurrent breast cancer. Am. J. Clin. Oncol.24(2), 185–191 (2001).
   PubMedGoogle Scholar
• Leonard RC, Lind M, Twelves C et al. Anglo-Celtic Co-operative Oncology Group. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J. Natl Cancer Inst.96(14), 1076–1083 (2004).
   PubMed Web of Science ®Google Scholar
• No Authors Listed. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet351(9114), 1451–1467 (1998).
   PubMed Web of Science ®Google Scholar
• Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N. Engl. J. Med.348(24), 2431–2442 (2003).
   PubMed Web of Science ®Google Scholar
• Wong ZW, Ellis MJ. First-line endocrine treatment of breast cancer: aromatase inhibitor or anti-oestrogen? Br. J. Cancer90(1), 20–25 (2004).
   PubMedGoogle Scholar
• Kauraniemi P, Hautaniemi S, Autio R et al. Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene23(4), 1010–1013 (2004).
   PubMed Web of Science ®Google Scholar
• Petit T, Borel C, Ghnassia JP et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin. Cancer Res.7(6), 1577–1581 (2001).
   PubMed Web of Science ®Google Scholar
• Hoff ER, Tubbs RR, Myles JL, Procop GW. HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am. J. Clin. Pathol.117(6), 916–921 (2002).
   PubMed Web of Science ®Google Scholar
• No Authors Listed. Cell Markers And Cytogenetics Committees College Of American Pathologists. Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch. Pathol. Lab. Med.126(7), 803–808 (2002).
   PubMed Web of Science ®Google Scholar
• Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: which test to use? J. Pathol.199(4), 411–417 (2003).
   PubMed Web of Science ®Google Scholar